eCite Digital Repository
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Citation
Dewar, AL and Cambareri, AC and Zannettino, ACW and Doherty, KV and Hughes, TP and Lyons, AB, Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib, Blood, 105, (8) pp. 3127-3132. ISSN 0006-4971 (2005) [Refereed Article]
 | PDF Restricted - Request a copy 339Kb |
Copyright Statement
Copyright 2005 The American Society of Hematology
DOI: doi:10.1182/blood-2004-10-3967
Abstract
Imatinib is a tyrosine kinase inhibitor that suppresses the growth of bcr-abl-expressing chronic myeloid leukemia (CML) progenitor cells by blockade of the adenosine triphosphate (ATP)-binding site of the kinase domain of bcr-abl. Imatinib also inhibits the c-abl, platelet-derived growth factor (PDGF) receptor, abl-related gene (ARG) and stem-cell factor (SCF) receptor tyrosine kinases, and has been used clinically to inhibit the growth of malignant cells in patients with CML and gastrointestinal stromal tumors (GISTs). Although initially considered to have minimal effects of normal hematopoiesis, recent studies show that imatinib also inhibits the growth of some nonmalignant hematopoietic cells, including monocyte/macrophages. This inhibition could not be attributed to the known activity profile of imatinib. Here, we demonstrate for the first time that imatinib targets the macrophage colony-stimulating factor (M-CSF) receptor c-fms. Phosphorylation of c-fms was inhibited by therapeutic concentrations of imatinib, and this was not due to down-regulation in c-fms expression. Imatinib was also found to inhibit M-CSF-induced proliferation of a cytokine-dependent cell line, further supporting the hypothesis that imatinib affects the growth and development of monocyte and/or macrophages through inhibition of c-fms signaling. Importantly, these results identify an additional biologic target to those already defined for imatinib. Imatinib should now be assessed for activity in diseases where c-fms activation is implicated, including breast and ovarian cancer and inflammatory conditions.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Immunology |
| Research Field: | Cellular immunology |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Clinical health not elsewhere classified |
| UTAS Author: | Lyons, AB (Associate Professor Bruce Lyons) |
| ID Code: | 73621 |
| Year Published: | 2005 |
| Web of Science® Times Cited: | 242 |
| Deposited By: | Medicine |
| Deposited On: | 2011-10-19 |
| Last Modified: | 2012-06-26 |
| Downloads: | 0 |
Repository Staff Only: item control page